Health
Follow-up Sinks Candesartan as Cardioprotection in Breast Cancer – Medscape
The new PRADA findings suggest cardioprotective drugs may not be necessary for all patients during adjuvant breast cancer therapy, the authors say.
After a modest early signal of benefit, candesartan cilexetil (Atacand, Cheplapharm) showed no effect on key markers of heart health 2 years after treatment in patients with early-stage breast cancer in the randomized PRADA trial.
The 2015 study was hailed at the time as the largest randomized trial in breast cancer to look at the effects of angiotensin-receptor blockade with candesartan and the -blocker metoprolol, both against placebo, on cardiac dysfunction. The 120 patients received adjuvant…
-
Noosa News21 hours agoBrisbane’s original 1979 electric trains take one last journey
-
General4 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General18 hours agoDr Daniel Hunt, Michael Long and Christine Anu celebrated at 50th NAIDOC Week Awards
-
Noosa News13 hours agoRainbow Beach surfer’s untold 7/7 story